Congress' massive spending deal includes two provisions related to the debate over drug prices -- one on the 340B drug discount program and one on hepatitis C drug prices. The report accompanying the legislation urges HHS to investigate whether the most vulnerable patients benefit from the 340B program, and it asks CMS to study the prevalence of hepatitis and the cost of treating the sickest patients. The 340B program, administered by HHS' Health Resources and Services Administration, makes drug makers...